Vera Therapeutics, Inc. - VERA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Kynam Capital Management, LP | 4.01% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Kynam Capital Management GP, LLC | 4.01% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Yue Tang | 4.01% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 6.4% | 4,573,684 | View |
| Apr 01, 2026 | SCHEDULE 13G | Point72 Asset Management, L.P. | 1.7% | 1,229,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | Point72 Capital Advisors, Inc. | 1.7% | 1,229,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | Steven A. Cohen | 1.7% | 1,229,525 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.